Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02892123
Title Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Zymeworks Inc.

Advanced Solid Tumor

gastroesophageal junction adenocarcinoma

Her2-receptor positive breast cancer

stomach carcinoma


Capecitabine + ZW25


Paclitaxel + ZW25

Vinorelbine + ZW25

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST